Supernus Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
SUPN
CUSIP
868459108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 868459108 since 12/18/2024, newest first.

Filer % of Class Filed
Millennium Management LLC 13G/A Amendment 2
6.6%
Checked 5% or less
8/6/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.0% 4/30/2026
Event 3/31/2026
Vanguard Portfolio Management LLC 13G 5.7% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 7 0% 3/27/2026
Event 3/13/2026
Millennium Management LLC 13G/A Amendment 1
5.7% 2/18/2026
Event 2/11/2026
Armistice Capital, LLC 13G/A Amendment 10
4.8% 2/17/2026
Event 12/31/2025
Millennium Management LLC 13G
5.3% 2/2/2026
Event 1/26/2026
Dimensional Fund Advisors LP 13G/A Amendment 1 4.7% 1/21/2026
Event 12/31/2025
Armistice Capital, LLC 13G/A Amendment 9
5.1% 11/14/2025
Event 9/30/2025
Armistice Capital, LLC 13G/A Amendment 7
9.3% 5/15/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 5 14.7% 4/22/2025
Event 3/31/2025
Armistice Capital, LLC 13G/A Amendment 6
8.8% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 12 122 k $5.26 M
2026 Q2 342 63.2 M $2.86 B
2026 Q1 339 58.2 M $3.01 B
2025 Q4 345 57.1 M $2.84 B
2025 Q3 319 57.9 M $2.77 B
2025 Q2 302 60.1 M $1.89 B
2025 Q1 303 59.3 M $1.94 B
2024 Q4 298 59.5 M $2.15 B
2024 Q3 279 60.2 M $1.88 B
2024 Q2 253 59.2 M $1.58 B
2024 Q1 264 58.2 M $1.98 B
2023 Q4 254 58.3 M $1.69 B
2023 Q3 246 57.0 M $1.57 B
2023 Q2 257 57.3 M $1.72 B
2023 Q1 270 55.8 M $2.01 B
2022 Q4 274 57.8 M $2.06 B
2022 Q3 251 55.7 M $1.89 B
2022 Q2 234 57.7 M $1.63 B
2022 Q1 242 53.8 M $1.75 B
2021 Q4 252 55.3 M $1.61 B
2021 Q3 236 54.4 M $1.45 B
2021 Q2 241 54.2 M $1.67 B
2021 Q1 236 53.4 M $1.40 B
2020 Q4 239 54.9 M $1.38 B
2020 Q3 218 51.5 M $1.07 B
2020 Q2 226 50.6 M $1.20 B
2020 Q1 218 49.5 M $895 M
2019 Q4 247 52.0 M $1.23 B
2019 Q3 257 51.4 M $1.41 B
2019 Q2 293 55.4 M $1.83 B
2019 Q1 303 54.0 M $1.89 B
2018 Q4 288 52.5 M $1.75 B
2018 Q3 308 53.3 M $2.68 B
2018 Q2 337 54.4 M $3.26 B
2018 Q1 324 51.5 M $2.35 B
2017 Q4 306 49.7 M $1.98 B
2017 Q3 294 50.9 M $2.04 B
2017 Q2 282 48.4 M $2.07 B
2017 Q1 264 46.5 M $1.45 B
2016 Q4 247 45.9 M $1.16 B
2016 Q3 232 46.2 M $1.14 B
2016 Q2 226 46.7 M $951 M
2016 Q1 222 44.9 M $685 M
2015 Q4 215 44.8 M $602 M
2015 Q3 190 46.9 M $671 M
2015 Q2 171 42.7 M $724 M
2015 Q1 126 40.5 M $489 M
2014 Q4 112 37.1 M $308 M
2014 Q3 98 35.6 M $310 M
2014 Q2 98 37.2 M $407 M
2014 Q1 93 33.4 M $299 M